Cargando…
Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
OBJECTIVE: Investigate the association between use of depot medroxyprogesterone acetate (DMPA) (an injectable progestin-only contraceptive) and leiomyoma development. METHODS: We conducted a cohort study in the Detroit, Michigan, area that involved four clinic visits at 20-month intervals over 5 yea...
Autores principales: | Harmon, Quaker E., Patchel, Stacy A., Zhao, Shanshan, Umbach, David M., Cooper, Tracy E., Baird, Donna D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015023/ https://www.ncbi.nlm.nih.gov/pubmed/35576339 http://dx.doi.org/10.1097/AOG.0000000000004745 |
Ejemplares similares
-
Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
por: Upson, Kristen, et al.
Publicado: (2020) -
Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial
por: Lukes, Andrea S., et al.
Publicado: (2019) -
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
por: Al-Hendy, Ayman, et al.
Publicado: (2022) -
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020) -
Uterine leiomyoma and its association with menstrual pattern and history of depo-medroxyprogesterone acetate injections
por: Amanti, L, et al.
Publicado: (2011)